{"groups":[{"description":"TRC102 50 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"FG000","title":"Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 75 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"FG001","title":"Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"FG002","title":"Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 75 mg/m\\^2 IV over 30-60 min day1","id":"FG003","title":"Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 50mg/day PO on days 1-4; Pemetrex 500mg/m\\^2 IV over 10 min day 1","id":"FG004","title":"Arm B, Dose Level 1 - 50mg TRC102 (Phase II)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}